Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Raninga, Prahlad V., Lee, Andy, Sinha, Debottam, Dong, Lan-feng, Datta, Keshava K., Lu, Xue, Kalita-de Croft, Priyakshi, Dutt, Mriga, Hill, Michelle, Pouliot, Normand, Gowda, Harsha, Kalimutho, Murugan, Neuzil, Jiri, Khanna, Kum Kum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196287/
https://www.ncbi.nlm.nih.gov/pubmed/32373211
http://dx.doi.org/10.7150/thno.42705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196287/
https://www.ncbi.nlm.nih.gov/pubmed/32373211
http://dx.doi.org/10.7150/thno.42705

Ejemplares similares